- Toronto General Hospital joins as the seventh global site in the LSALT peptide Phase II trial.
- Arch Biopartners (ACHFF, Financial) shifts recruitment focus to Canada, reducing involvement in Turkey.
- Ethics approval granted by University Health Network for Toronto General Hospital's participation.
Arch Biopartners Inc. (ACHFF) has announced that the University Health Network (UHN) Research Ethics Board has approved Toronto General Hospital to participate in its ongoing Phase II trial for the LSALT peptide. This trial aims to prevent and treat cardiac surgery-associated acute kidney injury (CS-AKI).
With this new approval, Toronto General Hospital becomes the seventh global site involved in the study, and the second site in Canada to begin patient recruitment. This strategic move is in line with Arch Biopartners' goal of diversifying geographic and demographic data.
LSALT peptide, the company’s lead drug candidate, targets the dipeptidase-1 (DPEP1) pathway and has shown promise in pre-clinical models in preventing ischemia-reperfusion injury (IRI) that leads to kidney damage. The trial, titled "Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide," aims to recruit 240 patients to evaluate the incidence of acute kidney injury within seven days after cardiac surgery, as defined by KDIGO criteria.
CS-AKI often occurs following cardiac procedures like coronary artery bypass grafting (CABG) and is associated with increased patient morbidity and mortality due to complications from acute kidney injury. Currently, there are no therapeutic treatments available to counteract this condition, making this trial pivotal in addressing this medical need.
Mr. Richard Muruve, CEO of Arch Biopartners, expressed his enthusiasm over the new development, noting the company's commitment to enhancing trial data through increased Canadian recruitment and reducing efforts in Turkey. This strategic shift is expected to provide more comprehensive data for evaluating the effectiveness of LSALT peptide in treating CS-AKI.
Arch Biopartners continues to advance its pipeline of drug candidates, focusing on preventing organ damage caused by inflammation and toxins, and the LSALT peptide represents a critical component in addressing these urgent medical challenges.
